SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-139476
Filing Date
2024-05-15
Accepted
2024-05-15 17:01:03
Documents
13
Period of Report
2024-05-09
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K d793808d8k.htm   iXBRL 8-K 22173
  Complete submission text file 0001193125-24-139476.txt   146881

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA algs-20240509.xsd EX-101.SCH 2835
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE algs-20240509_lab.xml EX-101.LAB 18737
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE algs-20240509_pre.xml EX-101.PRE 11697
16 EXTRACTED XBRL INSTANCE DOCUMENT d793808d8k_htm.xml XML 3780
Mailing Address ONE CORPORATE DR., 2ND FLOOR SOUTH SAN FRANCISCO CA 94080
Business Address ONE CORPORATE DR., 2ND FLOOR SOUTH SAN FRANCISCO CA 94080 (800) 466-6059
Aligos Therapeutics, Inc. (Filer) CIK: 0001799448 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39617 | Film No.: 24952317
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)